

# **Mydriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/M34BA958225DEN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: M34BA958225DEN

## **Abstracts**

The 7 major mydriasis markets are expected to exhibit a CAGR of 6.14% during 2024-2034.

The mydriasis market has been comprehensively analyzed in IMARC's new report titled "Mydriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mydriasis refers to a medical disorder in which the pupil of the eye remains abnormally dilated and fails to constrict properly in response to changes in lighting conditions or other stimuli. This can result in increased sensitivity to light, glare, and difficulties with vision, especially in a bright environment. Additionally, individuals suffering from mydriasis may experience blurred vision or problems with focusing, particularly when transitioning between different lighting conditions. The presence of other accompanying indications will depend on the underlying cause of mydriasis, which may include symptoms related to medication side effects, eye diseases, neurological disorders, or systemic conditions. The diagnostic process generally begins with a thorough medical history and physical examination, including an assessment of the eyes, neurological functioning, as well as the evaluation of any associated symptoms. Numerous specialized diagnostic procedures may be conducted, such as pupillometry to objectively measure pupillary responses, imaging studies like MRI or CT scans to assess structural abnormalities, and laboratory tests to investigate systemic conditions or drug-related causes.

The rising cases of several eye disorders, such as uveitis, iritis, glaucoma, ocular trauma, etc., that affect the normal functioning of the iris muscles are primarily driving the mydriasis market. Furthermore, the widespread adoption of alpha-adrenergic agonist eye drops, including apraclonidine or brimonidine, to constrict the dilated pupil

and reduce light sensitivity is acting as another significant growth-inducing factor. Additionally, the inflating utilization of pupil constriction exercises, which involve performing specific eye exercises that help in stimulating the muscles responsible for controlling the size of the pupil, is also augmenting the market growth. Moreover, the escalating demand for surgical procedures to correct anatomical issues, repair damaged structures, as well as alleviate underlying neurological problems that contribute to mydriasis is creating a positive outlook for the market. Apart from this, the ongoing advancements in imaging technologies, such as the introduction of high-resolution digital imaging and anterior segment optical coherence tomography, which have improved the visualization of the anterior segment of the eye, including the iris and pupil, are expected to drive the mydriasis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mydriasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mydriasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mydriasis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the mydriasis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the mydriasis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mydriasis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

Market Insights

How has the mydriasis market performed so far and how will it perform in the coming years?

What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the mydriasis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the mydriasis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of mydriasis across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of mydriasis by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of mydriasis by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with mydriasis across the seven major markets?

What is the size of the mydriasis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of mydriasis?

What will be the growth rate of patients across the seven major markets?

### Mydriasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for mydriasis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mydriasis market?

What are the key regulatory events related to the mydriasis market?

What is the structure of clinical trial landscape by status related to the mydriasis

market?

What is the structure of clinical trial landscape by phase related to the mydriasis market?

What is the structure of clinical trial landscape by route of administration related to the mydriasis market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 MYDRIASIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 MYDRIASIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 MYDRIASIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

## 7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2018-2023)

7.2.2 Epidemiology Forecast (2024-2034)

7.2.3 Epidemiology by Age (?2018-2034?)

7.2.4 Epidemiology by Gender (?2018-2034?)

7.2.5 Diagnosed Cases (?2018-2034?)

7.2.6 Patient Pool/Treated Cases (?2018-2034?)

## 7.3 Epidemiology Scenario - United States

7.3.1 Epidemiology Scenario (2018-2023)

7.3.2 Epidemiology Forecast (2024-2034)

7.3.3 Epidemiology by Age (?2018-2034?)

7.3.4 Epidemiology by Gender (?2018-2034?)

7.3.5 Diagnosed Cases (?2018-2034?)

7.3.6 Patient Pool/Treated Cases (?2018-2034?)

## 7.4 Epidemiology Scenario - Germany

7.4.1 Epidemiology Scenario (2018-2023)

7.4.2 Epidemiology Forecast (2024-2034)

7.4.3 Epidemiology by Age (?2018-2034?)

7.4.4 Epidemiology by Gender (?2018-2034?)

7.4.5 Diagnosed Cases (?2018-2034?)

7.4.6 Patient Pool/Treated Cases (?2018-2034?)

## 7.5 Epidemiology Scenario - France

7.5.1 Epidemiology Scenario (2018-2023)

7.5.2 Epidemiology Forecast (2024-2034)

7.5.3 Epidemiology by Age (?2018-2034?)

7.5.4 Epidemiology by Gender (?2018-2034?)

7.5.5 Diagnosed Cases (?2018-2034?)

7.5.6 Patient Pool/Treated Cases (?2018-2034?)

## 7.6 Epidemiology Scenario - United Kingdom

7.6.1 Epidemiology Scenario (2018-2023)

7.6.2 Epidemiology Forecast (2024-2034)

7.6.3 Epidemiology by Age (?2018-2034?)

7.6.4 Epidemiology by Gender (?2018-2034?)

7.6.5 Diagnosed Cases (?2018-2034?)

7.6.6 Patient Pool/Treated Cases (?2018-2034?)

## 7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 MYDRIASIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 MYDRIASIS - UNMET NEEDS**

## **10 MYDRIASIS - KEY ENDPOINTS OF TREATMENT**

## **11 MYDRIASIS - MARKETING PRODUCTS**

- 11.1 List of Mydriasis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Drug Name – Company Name
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 MYDRIASIS - PIPELINE DRUGS**

### 12.1 List of Mydriasis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Phenylephrine/tropicamide - Eyenovia

##### 12.1.1.1 Drug Overview

##### 12.1.1.2 Mechanism of Action

##### 12.1.1.3 Clinical Trial Results

##### 12.1.1.4 Safety and Efficacy

##### 12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. MYDRIASIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. MYDRIASIS – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

### 14.2 Drugs by Phase

### 14.3 Drugs by Route of Administration

### 14.4 Key Regulatory Events

## **15 MYDRIASIS - MARKET SCENARIO**

### 15.1 Market Scenario - Key Insights

### 15.2 Market Scenario - Top 7 Markets

#### 15.2.1 Mydriasis - Market Size

##### 15.2.1.1 Market Size (2018-2023)

##### 15.2.1.2 Market Forecast (2024-2034)

#### 15.2.2 Mydriasis - Market Size by Therapies

##### 15.2.2.1 Market Size by Therapies (2018-2023)

##### 15.2.2.2 Market Forecast by Therapies (2024-2034)

### 15.3 Market Scenario - United States

#### 15.3.1 Mydriasis - Market Size

##### 15.3.1.1 Market Size (2018-2023)

##### 15.3.1.2 Market Forecast (2024-2034)

#### 15.3.2 Mydriasis - Market Size by Therapies

##### 15.3.2.1 Market Size by Therapies (2018-2023)

##### 15.3.2.2 Market Forecast by Therapies (2024-2034)

- 15.3.3 Mydriasis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Mydriasis - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Mydriasis - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Mydriasis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Mydriasis - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Mydriasis - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Mydriasis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Mydriasis - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Mydriasis - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Mydriasis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Mydriasis - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Mydriasis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Mydriasis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Mydriasis - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Mydriasis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)

- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Mydriasis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Mydriasis - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Mydriasis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Mydriasis - Access and Reimbursement Overview

## **16 MYDRIASIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 MYDRIASIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 MYDRIASIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Mydriasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M34BA958225DEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M34BA958225DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

